Oruka Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
ORKA$109.50+4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development(1) | $53,696 | $28,988 | $126,098 | $73,000 |
| General and administrative(2) | 8,440 | 5,117 | 22,579 | 14,620 |
| Total operating expenses | 62,136 | 34,105 | 148,677 | 87,620 |
| Loss from operations | (62,136) | (34,105) | (148,677) | (87,620) |
| Other income (expense): | ||||
| Interest income | 12,166 | 3,832 | 25,669 | 11,781 |
| Other income (expense), net | 5 | (4) | 17 | (11) |
| Total other income, net | 12,171 | 3,828 | 25,686 | 11,770 |
| Net loss | $(49,965) | $(30,277) | $(122,991) | $(75,850) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.63) | $(0.55) | $(1.67) | $(1.40) |
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $(52.40) | $(45.46) | $(139.45) | $(116.94) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 71,590,343 | 44,067,059 | 63,268,180 | 42,622,935 |
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 94,497 | 137,138 | 122,768 | 137,138 |
| (1) | Includes related party amounts of nil and $9,595 for the three months ended September 30, 2026 and 2025, respectively, and $3,000 and $15,998 for the nine months ended September 30, 2026 and 2025, respectively. |
| (2) | Includes related party amounts of $50 and $8 for the three months ended September 30, 2026 and 2025, respectively, and $54 and $130 for the nine months ended September 30, 2026 and 2025, respectively. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.